2-((5-fluoro-6-(4-fluorophenoxy)pyridin-3-yl)methoxy)-9-methoxy-6,7-dihydro-4H-pyrimido[6,1-a]isoquinolin-4-one | 1369253-41-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-((5-fluoro-6-(4-fluorophenoxy)pyridin-3-yl)methoxy)-9-methoxy-6,7-dihydro-4H-pyrimido[6,1-a]isoquinolin-4-one
• 英文别名: 2-[[5-Fluoro-6-(4-fluorophenoxy)pyridin-3-yl]methoxy]-9-methoxy-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one
• CAS: 1369253-41-7
• 化学式: C₂₅H₁₉F₂N₃O₄
• 分子量: 463.44
• InChiKey: RGVMGIFKVHGFNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  73.2
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• [EN] TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES<br/>[FR] COMPOSÉS TRICYCLIQUES, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS
  申请人：GLAXO GROUP LTD

  公开号：WO2012037782A1

  公开（公告）日：2012-03-29

  The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.

  本发明涉及抑制Lp-PLA2活性的新化合物，以及它们的制备方法、含有它们的组合物，以及它们在治疗与Lp-PLA2活性相关的疾病中的应用，例如动脉粥样硬化、阿尔茨海默病和/或糖尿病黄斑水肿。
• 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL) CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE
  申请人：JOHNSON MICHAEL R.

  公开号：US20130178482A1

  公开（公告）日：2013-07-11

  The present invention relates to the compound of the formula: or pharmaceutically acceptable salts thereof, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.

  本发明涉及以下化合物的公式：或其药学上可接受的盐，以及含有该化合物的组合物，制备该化合物的方法，以及用于促进黏膜表面水化和治疗疾病的治疗方法，包括慢性阻塞性肺疾病（COPD），哮喘，支气管扩张，急性和慢性支气管炎，囊性纤维化，肺气肿和肺炎。
• 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE
  申请人：Parion Sciences, Inc.

  公开号：US20140107133A1

  公开（公告）日：2014-04-17

  The present invention relates to the compound of the formula: or pharmaceutically acceptable salts thereof, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.

  本发明涉及以下化合物的配方： 或其药学上可接受的盐，以及含有该化合物的组合物，用于促进粘膜表面的水合作用和治疗包括慢性阻塞性肺疾病（COPD）、哮喘、支气管扩张、急性和慢性支气管炎、囊性纤维化、肺气肿和肺炎等疾病的治疗方法。
• TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES
  申请人：Glaxo Group Limited

  公开号：EP2619203A1

  公开（公告）日：2013-07-31
• US8669262B2
  申请人：——

  公开号：US8669262B2

  公开（公告）日：2014-03-11